ARDX
Price
$3.13Alerts
Change
+$0.12 (+3.99%)
Updated
Nov 11 closing price
Capitalization
743.58M
105 days until earnings call
Intraday BUY SELL Signals
MLTX
Price
$13.51Alerts
Change
+$0.95 (+7.56%)
Updated
Nov 11 closing price
Capitalization
981.28M
112 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ARDX vs MLTX

ARDX vs MLTX Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ARDX vs. MLTX commentary
Nov 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARDX is a StrongBuy and MLTX is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for ARDX with price predictions
Nov 11, 2026

Momentum Indicator for ARDX turns positive, indicating new upward trend

ARDX saw its Momentum Indicator move above the 0 level on November 10, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 80 similar instances where the indicator turned positive. In 69 of the 80 cases, the stock moved higher in the following days. The odds of a move higher are at 86%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ARDX's RSI Oscillator exited the oversold zone, 25 of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 49 of 60 cases where ARDX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.

Following a +6.83% 3-day Advance, the price is estimated to grow further. Considering data from situations where ARDX advanced for three days, in 221 of 265 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARDX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.

ARDX broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for ARDX entered a downward trend on November 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 11 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 30 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 79 (best 1 - 100 worst), indicating slightly worse than average price growth. ARDX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 79 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARDX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.

The Tickeron Valuation Rating of 97 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.990) is normal, around the industry mean (3.498). P/E Ratio (-12.522) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (50.260) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (1.846) is also within normal values, averaging (440.869).

The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

A.I.Advisor
a Summary for MLTX with price predictions
Nov 11, 2026

MLTX in upward trend: price rose above 50-day moving average on November 09, 2026

MLTX moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend. In 40 of 45 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 89%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where MLTX's RSI Oscillator exited the oversold zone, 11 of 16 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 69%.

The Momentum Indicator moved above the 0 level on November 09, 2026. You may want to consider a long position or call options on MLTX as a result. In 83 of 107 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 78%.

The Moving Average Convergence Divergence (MACD) for MLTX just turned positive on October 20, 2026. Looking at past instances where MLTX's MACD turned positive, the stock continued to rise in 42 of 53 cases over the following month. The odds of a continued upward trend are 79%.

The 10-day moving average for MLTX crossed bullishly above the 50-day moving average on November 11, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 15 of 20 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 75%.

Following a +16.85% 3-day Advance, the price is estimated to grow further. Considering data from situations where MLTX advanced for three days, in 257 of 306 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MLTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.

MLTX broke above its upper Bollinger Band on November 11, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for MLTX entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 38 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.292) is normal, around the industry mean (3.498). P/E Ratio (-3.003) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).

The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating steady price growth. MLTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Profit vs. Risk Rating rating for this company is 95 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MLTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

FUNDAMENTALS RATINGS
ARDX vs MLTX: Fundamental Ratings
ARDX
MLTX
OUTLOOK RATING
1..100
3237
VALUATION
overvalued / fair valued / undervalued
1..100
97
Overvalued
38
Fair valued
PROFIT vs RISK RATING
1..100
7995
SMR RATING
1..100
9798
PRICE GROWTH RATING
1..100
7958
P/E GROWTH RATING
1..100
1112
SEASONALITY SCORE
1..100
3085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MLTX's Valuation (38) in the null industry is somewhat better than the same rating for ARDX (97) in the Biotechnology industry. This means that MLTX’s stock grew somewhat faster than ARDX’s over the last 12 months.

ARDX's Profit vs Risk Rating (79) in the Biotechnology industry is in the same range as MLTX (95) in the null industry. This means that ARDX’s stock grew similarly to MLTX’s over the last 12 months.

ARDX's SMR Rating (97) in the Biotechnology industry is in the same range as MLTX (98) in the null industry. This means that ARDX’s stock grew similarly to MLTX’s over the last 12 months.

MLTX's Price Growth Rating (58) in the null industry is in the same range as ARDX (79) in the Biotechnology industry. This means that MLTX’s stock grew similarly to ARDX’s over the last 12 months.

ARDX's P/E Growth Rating (11) in the Biotechnology industry is in the same range as MLTX (12) in the null industry. This means that ARDX’s stock grew similarly to MLTX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARDXMLTX
RSI
ODDS (%)
Bullish Trend 1 day ago
86%
Bullish Trend 1 day ago
69%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
82%
Bearish Trend 1 day ago
83%
Momentum
ODDS (%)
Bullish Trend 1 day ago
86%
Bullish Trend 1 day ago
78%
MACD
ODDS (%)
N/A
Bullish Trend 1 day ago
79%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
79%
Bullish Trend 1 day ago
83%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
81%
Bullish Trend 1 day ago
87%
Advances
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 4 days ago
84%
Declines
ODDS (%)
Bearish Trend 7 days ago
80%
Bearish Trend 8 days ago
80%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
77%
Bearish Trend 1 day ago
84%
Aroon
ODDS (%)
Bearish Trend 1 day ago
80%
Bearish Trend 1 day ago
87%
COMPARISON
Comparison
Nov 12, 2026
Stock price -- (ARDX: $3.13 vs. MLTX: $13.51)
Brand notoriety: ARDX and MLTX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARDX: 69% vs. MLTX: 109%
Market capitalization -- ARDX: $743.58M vs. MLTX: $981.28M
ARDX [@Biotechnology] is valued at $743.58M. MLTX’s [@Biotechnology] market capitalization is $981.28M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARDX’s FA Score shows that 1 FA rating(s) are green while MLTX’s FA Score has 1 green FA rating(s).

  • ARDX’s FA Score: 1 green, 4 red.
  • MLTX’s FA Score: 1 green, 4 red.
According to our system of comparison, MLTX is a better buy in the long-term than ARDX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARDX’s TA Score shows that 4 TA indicator(s) are bullish while MLTX’s TA Score has 6 bullish TA indicator(s).

  • ARDX’s TA Score: 4 bullish, 3 bearish.
  • MLTX’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, MLTX is a better buy in the short-term than ARDX.

Price Growth

ARDX (@Biotechnology) experienced а -4.86% price change this week, while MLTX (@Biotechnology) price change was +16.87% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.49%. For the same industry, the average monthly price growth was -6.84%, and the average quarterly price growth was -13.86%.

Reported Earning Dates

ARDX is expected to report earnings on Feb 25, 2027.

MLTX is expected to report earnings on Mar 04, 2027.

Industries' Descriptions

@Biotechnology (-0.49% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

ARDX and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARDX has been loosely correlated with VCYT. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if ARDX jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARDX
1D Price
Change %
ARDX100%
+3.99%
VCYT - ARDX
45%
Loosely correlated
+4.36%
IMNM - ARDX
40%
Loosely correlated
+2.25%
ELVN - ARDX
39%
Loosely correlated
-0.02%
ARQT - ARDX
39%
Loosely correlated
+3.63%
MLTX - ARDX
37%
Loosely correlated
+7.56%
More

MLTX and

Correlation & Price change

A.I.dvisor indicates that over the last year, MLTX has been closely correlated with KALA. These tickers have moved in lockstep 82% of the time. This A.I.-generated data suggests there is a high statistical probability that if MLTX jumps, then KALA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MLTX
1D Price
Change %
MLTX100%
+7.56%
KALA - MLTX
82%
Closely correlated
N/A
CGON - MLTX
50%
Loosely correlated
-0.04%
ELVN - MLTX
47%
Loosely correlated
-0.02%
XENE - MLTX
44%
Loosely correlated
+1.72%
BDTX - MLTX
42%
Loosely correlated
+0.94%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
PLSM1.580.09
+6.04%
Pulsenmore Ltd.
NMR9.690.18
+1.89%
Nomura Holdings
SIM24.36N/A
N/A
Groupo Simec SAB de CV
CGBD11.40-0.02
-0.18%
Carlyle Secured Lending
MNSB21.55-0.17
-0.78%
MainStreet Bancshares